Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413492 | 1.00 | TAS1R3 (0.37) | TAS1R3TAS1R1TP53LMNAMAPT | |
| SCHEMBL2411287 | 0.93 | CD274 (0.33) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2411289 | 0.93 | CD274 (0.33) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2409805 | 0.92 | CD274 (0.33) | TP53LMNAMAPTCD274PDCD1LG2 | |
| SCHEMBL2412907 | 0.92 | CD274 (0.33) | TP53LMNAMAPTCD274PDCD1LG2 | |
| SCHEMBL2409808 | 0.92 | CD274 (0.33) | TP53LMNAMAPTCD274PDCD1LG2 | |
| SCHEMBL2414296 | 0.91 | CD274 (0.33) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2414295 | 0.91 | CD274 (0.33) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2410900 | 0.90 | TAS1R3 (0.30) | TAS1R3TAS1R1 | |
| SCHEMBL2410902 | 0.90 | TAS1R3 (0.30) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | TAS1R3 3611/4885TAS1R1 3064/4885TP53 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.